A Platform Cell Therapy To Restore Vision
Date & Time
April 4, 4:00 PM ET / 1:00 PM PT
Webinar Details provided upon RSVP Approval
About the Event
jCyte is developing jCell, a first-in-class platform cell therapy that holds the potential to restore vision in the millions of people worldwide with blinding retinal diseases. Recent Phase 2b clinical results in Retinitis Pigmentosa have shown excellent safety and efficacy to date, with many patients having regained years of prior lost vision.
Join our webinar with the jCyte leadership team to learn more about what the company’s FDA RMAT designation, support from CIRM, and other strategic partnerships mean for the path forward.